Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Prism Pharmaceuticals to bring in up to $68mm with financing

14 Sep 2018

Executive Summary

Prism Pharmaceuticals (developing cardiovascular therapeutics for the acute care setting) has received $23mm with the sale of preferred shares to Paul Capital Partners' Paul Royalty Fund II and current backer Essex Woodlands Health Ventures. Prism gets another $45mm if it reaches predetermined milestones. Concurrent with the financing, two representatives from Paul Royalty will take seats on Prism's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Other
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By